High-risk HPV is not associated with epithelial ovarian cancer in a Caucasian population by Kasper Ingerslev et al.
RESEARCH ARTICLE Open Access
High-risk HPV is not associated with
epithelial ovarian cancer in a Caucasian
population
Kasper Ingerslev1*, Estrid Hogdall2, Wojciech Skovrider-Ruminski2, Tine Henrichsen Schnack2,3,
Mona Aarenstrup Karlsen4, Lotte Nedergaard5, Claus Hogdall3 and Jan Blaakær1
Abstract
Background: High-risk human papillomavirus (HPV) has been suspected to play a role in the carcinogenesis of
epithelial ovarian cancer (EOC). However, results from previous studies are conflicting. In most of these studies, the
number of tissue samples was small. The current study was therefore undertaken to examine the prevalence of
high-risk HPV DNA in EOC in a large series of patients.
Method: Formalin-fixed, paraffin-imbedded tumor tissue samples from 198 cases consecutively included in the
Danish Pelvic Mass Study were analyzed. The material included 163 serous adenocarcinomas, 15 endometrioid
adenocarcinomas, 11 mucinous adenocarcinomas and nine clear-cell carcinomas. Genotyping for high-risk HPV
DNA was performed by real-time Polymerase chain reaction (PCR) using an in-house TaqMan singleplex assay
targeting the E6/E7 region of the HPV 16 and 18 genomes. Additionally, 20 random samples without HPV 16
and/or 18 infections were reanalyzed for HPV subtypes 31, 33, 35, 39, 45, 51 and 52.
Results: The quality criteria were fulfilled in 191 samples. HPV 18 DNA was detected in one sample only, while the
rest tested negative. The subgroup analysis for seven additional high-risk HPV subtypes was also negative.
Conclusions: Only one in 191 samples was positive for HPV DNA. We therefore conclude that high risk HPV is
unlikely to be associated with EOC in a Caucasian population. Future studies should focus on other microorganisms
as possible etiological factors in EOC carcinogenesis.
Keywords: Human papillomavirus, Ovarian cancer, Viral carcinogenesis
Background
Epithelial ovarian cancer (EOC) is the most lethal cancer
of all the gynecological cancers. It is characterized by
late and unspecific onset of symptoms and thus the
presence of disseminated disease at the time of diagnosis
[1]. Ten percent of EOC cases are estimated to be
caused by genetic mutations, most notably BRCA1 and
BRCA2 mutations [2]. An inverse association with the
number of ovulatory cycles has also been postulated due
to the protective effect of parity and oral contraceptives
on EOC risk [3]. Despite of these findings, the etiology
of EOC is still largely unknown. A current theory
hypothesizes that pelvic infection and inflammation may
play a role in the carcinogenesis of EOC [4, 5]. The the-
ory is supported by epidemiological data that describes a
protective effect on EOC of factors that interrupt the
passage to the peritoneal cavity from the vagina. This
applies, for instance, to tubal ligation, salpingectomy and
hysterectomy [6–8]. Due to the known association
between human papillomavirus (HPV) and cervical,
vaginal, vulvar, anal and oropharyngeal cancers, the
focus has primarily been directed toward high-risk HPV
[9, 10]. However, previous data are conflicting. Several
studies have found an association between HPV and
EOC [11–14], whereas others have not [15–18]. Thus,
the possible association remains unclear. Previous stud-
ies are characterized by a small number of included pa-
tients with EOC, resulting in limited statistical power.
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Additionally, not all studies stratified their analysis by
EOC subtype. This stratification is important since EOC
subtypes are believed to develop through different
pathogenetic pathways [19, 20], and therefore, it may be
assumed that the etiologic factors differ among subtypes.
The current study was therefore undertaken to deter-
mine the prevalence of high-risk HPV DNA in EOC tis-
sue from a large group of patients. We used real-time
PCR assays on DNA extracted from 198 tumor tissue
samples from EOC patients. Full pathology information
was obtained for all patients, allowing positive results to
be correlated with EOC subtype.
Material
The study was a part of the Danish Pelvic Mass Study, a
prospective, ongoing collection of blood and tumor tis-
sue samples. Oral and written consent were given by
each patient before enrollment, and the Danish Ethical
Committee approved the study protocol (KF01-227/03
and KF01-143/04, H-3-2010-022). Ninety-five percent of
patients that were eligible for inclusion accepted to par-
ticipate. In the period from 2004–2010, 246 patients
with EOC were consecutively included. The study was a
single center study (Copenhagen University Hospital) in
the first few years, accounting for the relatively low rate
of inclusion. The study has since expanded to be nation-
wide. The patients were included when admitted to the
tertiary center, the Gynecologic Clinic, Copenhagen
University Hospital, Copenhagen, Denmark due to a pel-
vic mass or pelvic pains potentially caused by EOC. Pa-
tients with preoperatively known relapse of previous
cancer or an active cancer other than EOC were ex-
cluded. Forty-eight patients were excluded for the fol-
lowing reasons: 24 patients were excluded due to
insufficient tumor tissue for analysis. Fifteen patients
were excluded since they had been treated with neoadju-
vant chemotherapy. An additional eight patients were
excluded after pathology revision, since two patients did
not have EOC, four patients had carcinosarcomas and
two patients had an additional cancer diagnosis. Patients
were examined according to the Danish Cancer Fast
Track Guidelines. All patient data were registered con-
tinuously online in the Danish Gynecologic Cancer
Database by gynecologists, pathologists and oncologists.
Biological material was collected and stored at the time
of surgery through the Danish Cancer Biobank [21]. For
the present study, formalin-fixed and paraffin-embedded
(FFPE) EOC tumor samples from 198 consecutively in-
cluded patients were used.
Methods
A pathologist, specialized in gynecological oncology,
revised tumor FFPE material and a 2-mm biopsy punch
was then used to sample the tumor tissue. DNA
extraction was carried out on a Qiagen® Qiacube using
the DNA FFPE kit. DNA concentration was measured
on Nanodrop® and diluted to 5 ng/μl. Genotyping was
performed with an in-house singleplex assay based on
published studies by Lindh et al. [22] for subtypes 16
and 18. The sensitivity of the assay was not specified in
the original article [22]. However, the method was vali-
dated by the group against a linear array from Roche
with high concordance. We have used the assay previ-
ously and have successfully detected a HPV DNA preva-
lence under one percent [23]. We therefore estimate
that the sensitivity is below one percent. The assay con-
sisted of TaqMan singleplex real-time PCR targeting the
E6/E7 region of the HPV genome. Probes and corre-
sponding primers were chosen with specificity for each
HPV genotype using a housekeeping glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) as positive DNA
reference. Additionally, 20 random samples without
HPV 16 and 18 infections were further analyzed with an
in-house singleplex assay for detection of HPV subtypes
31, 33, 35, 39, 45, 51 and 52 based on the method de-
signed by Lindh et al. [22]. Real-time PCR was per-
formed on the Roche®LC480 Lightcycler with the
following cycling parameters: 50 °C for 5 min, 95 °C for
10 min followed by 50 cycles at 95 °C for 15 s, 58 °C for
1 min. A cycle threshold < 35 was used in the interpret-
ation of the PCR results according to the recommenda-
tions in the original assay design. Each PCR reaction
included 0.5 μM primer and 0.2 μM probe in 25 μl
volume. Additionally, 12.5 μl TaqMan universal mas-
termix with Uracil-DNA Glycosylase including 5 μl
sample template was added per well. There were two
negative controls. A no template control (NTC) and a
wildtype human DNA (TaqMan® Control Genomic DNA
(human) Catalog number: 4312660). Controls were in-
cluded in all runs.
Results
The tissue material included in this study consisted of
163 serous adenocarcinomas (82.3 %), 15 endometrioid
adenocarcinomas (7.6 %), 11 mucinous adenocarcinomas
(5.5 %) and nine clear cell neoplasms (4.5 %). The
International Federation of Gynecology and Obstetrics
(FIGO) stage distribution of the study population was as
follows: 31 had stage I EOC (15.7 %), 20 patients had
stage II (10.1 %), 122 had stage III (61.6 %) and 25 had
stage IV EOC (12.6 %). The median age was 64 years
(range 31–89 years). No differences in age, stage and
distribution of histology were found between the 198
included patients with EOC and the 24 patients with
EOC excluded due to insufficient tumor tissue. Please
be referred to Table 1. The quality criteria for the
real-time PCR analyses were fulfilled in 191 samples;
seven samples yielded a cycle threshold score above
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35 and were excluded due to low amounts of DNA
material. HPV 18 DNA was detected in one of the
191 samples (Fig. 1). The HPV-positive tumor sample
was a serous adenocarcinoma, FIGO stage IB. The
patient was 57 years old at the time of diagnosis.
Serum CA125 was 96 U/mL. None of the tumor
samples were HPV 16 positive. Furthermore, none of
the 20 samples analyzed for HPV subtypes 31, 33, 35,
39, 45, 51 and 52 tested positive.
Discussion
The carcinogenic potential of high-risk HPV is well de-
scribed and includes several mechanisms. Viral onco-
genes E6 and E7 are pivotal elements, since expression
of these genes impairs the function of host-cell tumor
suppressors p53 and retinoblastoma protein, thus favor-
ing malignant transformation [23, 24]. Furthermore,
molecular studies have demonstrated the capability of
E6 and E7 to target cellular factors like paxillin, tuberin,
E6-AP, E6-BP, E6TP1 and TNFR-1 as well as cell cycle
regulators such as cyclins, cyclin-dependent kinases and
CDKs-inhibitors [24–26]. The resulting suppression of
apoptosis and the prolongation of the cell life span
maximize HPV DNA replication in the infected cell.
High-risk HPV is an established etiological factor in ano-
genital and oropharyngeal cancers [9, 10]. The role of
HPV in the carcinogenesis of EOC is controversial. Our
study indicates that HPV is unlikely to be involved in
EOC carcinogenesis in the Danish population as only
one of 191 DNA sample was HPV 18 positive and none
were positive for HPV 16. Furthermore, additional test-
ing for several other HPV subtypes confirmed that these
HPV subtypes were also found to be negative. This is in
line with several previous studies, although results are
conflicting (Table 2) [11, 12, 15, 16, 18, 26–35].













163(82.3 %) 17(70.8 %)
Mucinous adenocarcinoma,
n (%)
11(5.6 %) 1(4.2 %)
Endometrioid adenocarcinoma,
n (%)
15(7.6 %) 3(12.5 %)
Clear Cell carcinoma, n (%) 9(4.5 %) 3(12.5 %)
Tumor stage 0.494
Stage I, n (%) 31(15.7 %) 6(25.0)
Stage II, n (%) 21(10.6 %) 1(4.2 %)
Stage III, n (%) 120(60.1 %) 13(54.2 %)
Stage IV, n (%) 26(13.1 %) 4(16.7 %)
Age, median (range) 64(58) 62(53) 0.414
Abbreviations: EOC epithelial ovarian cancer, Tumor stage the international
federation of gynecology and obstetrics (FIGO) stage
Fig. 1 Results of real-time PCR amplification. Amplification curve showing a positive detection of HPV 18 DNA and housekeeping gene GAPDH.
HPV 16 in negative
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The strength of the present study was the large number of
samples compared to previous studies. In addition, the
detailed description of the characteristics of the patients, in-
cluding information on tumor histology and FIGO stage,
should be noted. Some limitations should also be addressed.
Indeed, HPV DNA detection may be less optimal in FFPE
tumor material compared to fresh frozen tissue due to nu-
cleic acid degradation [35, 36]. Recently we have, however,
successfully demonstrated HPV DNA in 90 % of anal can-
cers using a comparable FFPE material in the same labora-
tory [23, 36]. Moreover, the previous studies with the highest
reported HPV prevalences used FFPE material [11, 13 32,
33] (Table 2). Our study did not include a control group.
However, since we report a very low prevalence of HPV
DNA, it is our opinion that a control group would not alter
the conclusions of the study. Another limitation is that signs
of HPV infection may be lost in the interval between the pri-
mary infection and the diagnosis of cancer. For comparison,
the time between primary HPV infection and the develop-
ment of cancer of the cervix uteri has been estimated to be
15–20 years [37]. However, in other HPV-related cancers,
such as cervical and anal cancer, viral DNA is present in the
malignant tumor tissue and not exclusively in the precancer-
ous lesions [38, 39]. Moreover, continuous expression of viral
oncogenes is considered necessary for the sustenance of the
malignant phenotype in cancers associated with HPV [40].
In the event that HPV is involved in the pathogenesis of
EOC, we would therefore expect that HPV DNA would still
be present. A number of aspects could account for the con-
flicting results of the available studies on EOC and HPV.
Firstly, different analyzing methods were used. For instance,
Wu et al. used both In situ hybridization and immunohisto-
chemistry on the same 50 FFPE EOC samples and detected
HPV 16 DNA in 52 % and 36 % of samples, respectively
[13]. In addition, differences in race or country of origin may
play a role. Studies from Asia generally report higher preva-
lence of HPV in EOC tumor tissues than studies from the
Western countries [35, 36]. This is in support of our findings.
Several factors could account for this difference. Firstly, HPV
may be more prevalent in some regions of the World and
most notably in the developing countries [41]. Another fac-
tor could be the distribution of more virulent high-risk HPV
strains in Asia [42], or that the Asian populations have a
higher genetic susceptibility to HPV-induced carcinogenesis,
e.g. through expression of certain variants of polymorphisms
like the TNFA-308G/A (rs1800629) and -238G/A (rs361525)
or the p53 codon 72 polymorphism [43]. Despite the high
Asian prevalence of HPV in EOC tissue, the overall preva-
lence of ovarian cancer is lower in Asian countries compared
to Western countries [44]. This speaks against a connection
Table 2 Studies published during the last 20 years, reporting on HPV prevalence in EOC tissue










Asia 247 81 32.8
Shanmughapriya et al. 2012 [14] India Fresh PCR 6 24 6 25
Atalay et al. 2007 [30] Turkey FFPE PCR 16,33 94 8 8.5
Kuscu et al. 2005 [57] Turkey FFPE In situ
hybridization
Not specified 40 15 37.5
Wu et al. 2003 [13] China FFPE In situ
hybridization
16,18 50 26 52
Li et al. 2002 [33] China FFPE PCR Not specified 39 26 66.7
Europe, Western 274 1 0.4
Idahl et al. 2010 [18] Sweden Fresh frozen PCR 52 0 0
Giordano et al. 2008 [12] Italy FFPE PCR Not specified 50 1 2
Wentzensen et al. 2008 [29] Germany FFPR PCR 74 0 0
Anttila et al. 1999 [15] Finland FFPE PCR 98 0 0
Europe, Eastern 71 16 22.5
Bilyk et al. 2011 [28] Ukraine FFPE PCR 16,18 53 9 17
Zimna et al. 1997 [35] Poland Fresh frozen PCR 18 18 7 38.9
Middle East 100 42 42
Al-Shabanah et al. 2013 [11] Saudi Arabia FFPE PCR 16,18,45 100 42 42
USA 36 0 0
Quirk et al. 2006 [16] USA Fresh frozen PCR 16 0 0
Chen et al. 1999 [34] USA FFPE PCR 20 0 0
Abbreviations: EOC epithelial ovarian cancer, PCR polymerase chain reaction, HPV human papillomavirus, FFPE formalin-fixed paraffin-embedded
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between EOC and HPV even though the etiology of EOC is
most likely multi-factorial.
Our results do not support the theory that HPV is associ-
ated with EOC. However, other microorganisms may play a
role in the development of EOC. Thus, pelvic inflammatory
disease (PID) has been associated with an increased risk of
EOC in some epidemiological studies that also report a
dose–response effect, with more episodes of PID associated
with a stronger risk of EOC [45, 46]. Other studies, however,
have not confirmed this association [47–49]. Inflammatory
cells can promote neoplastic transformation by the induc-
tion of angiogenesis, invasion and metastasis and through
the release of mutagenic reactive oxygen species [50]. If an
association between EOC and PID exists, it is therefore
still unclear whether the microorganisms involved are dir-
ectly carcinogenic or indirectly promotes a carcinogenic
microenvironment by inducing tissue inflammation. In-
deed, inflammation is also a key point in the incessant
ovulation theory that is characterized by repetitive dam-
age, resulting in inflammation in the ovarian surface epi-
thelium [33]. Pelvic inflammation is also a characteristic of
endometriosis, and the condition has been associated with
increased risk of especially clear-cell and endometrioid
carcinomas [51]. However, a direct or combined mechan-
ism is also possible since in vitro models have demon-
strated a carcinogenic potential of common bacterial and
viral pathogens involved in PID [52–54]. Serous EOC is
suspected to originate in the precursor lesions in the distal
fallopian tubes [55], and the tubes are often affected by PID
[56]. Therefore, neoplastic or precancerous lesions from
the fallopian tubes may be more suitable candidates for
future studies on EOC and PID. Conclusively, the role of
PID in EOC is still controversial, and more studies includ-
ing a broader range of microorganisms are warranted.
Conclusion
The present comprehensive study of 198 patients with EOC
does not support an association between high-risk HPV in-
fection and EOC. It confirms the findings from previous,
smaller, studies that also report no or little association in
Western countries. Future studies examining the role of
infectious agents involved in the pathogenesis of EOC
should focus on other microorganisms as possible etio-
logical factors in EOC carcinogenesis.
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